Whereas delays in publication appear reasonable over a period of months, many were not published in full over a period of years and others would appear to be unlikely to ever be published. Further research should investigate the impact of publication delays on the availability of new drug treatments in clinical practic
1. Reprinted with permission from the American Society of Clinical Oncology.2. This article is hoste...
The United States (US) Food and Drug Administration (FDA) approves new drugs based on sponsor-submit...
Background: When the publication of important trial data is delayed, or data are never publish...
Objectives: To identify the expected delay between publication of conference abstracts and full publ...
Objectives: To identify the expected delay between publication of conference abstracts and full publ...
Very little is known about the proportion of oncology trials that get published, the time it takes t...
BACKGROUND: It has been suggested that a time-lag bias exists whereby research studies with striking...
INTRODUCTION: Treatment delays are significantly associated with increased mortality risk among adul...
AbstractBackgroundWhen the publication of important trial data is delayed, or data are never publish...
There is always an interval between the first symptoms, time to diagnosis and start of treatment in ...
<div><p>Objective</p><p>To characterize and quantify barriers towards the publication of academic dr...
Item does not contain fulltextWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Randomized active control tr...
Background: Treatment decisions should ideally be based on well-designed randomized controlled trial...
In 2005, we performed the largest survey on clinical trials of biotherapies for all solid tumors and...
Objective To evaluate the extent of non-publication or delayed publication of registered randomized...
1. Reprinted with permission from the American Society of Clinical Oncology.2. This article is hoste...
The United States (US) Food and Drug Administration (FDA) approves new drugs based on sponsor-submit...
Background: When the publication of important trial data is delayed, or data are never publish...
Objectives: To identify the expected delay between publication of conference abstracts and full publ...
Objectives: To identify the expected delay between publication of conference abstracts and full publ...
Very little is known about the proportion of oncology trials that get published, the time it takes t...
BACKGROUND: It has been suggested that a time-lag bias exists whereby research studies with striking...
INTRODUCTION: Treatment delays are significantly associated with increased mortality risk among adul...
AbstractBackgroundWhen the publication of important trial data is delayed, or data are never publish...
There is always an interval between the first symptoms, time to diagnosis and start of treatment in ...
<div><p>Objective</p><p>To characterize and quantify barriers towards the publication of academic dr...
Item does not contain fulltextWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Randomized active control tr...
Background: Treatment decisions should ideally be based on well-designed randomized controlled trial...
In 2005, we performed the largest survey on clinical trials of biotherapies for all solid tumors and...
Objective To evaluate the extent of non-publication or delayed publication of registered randomized...
1. Reprinted with permission from the American Society of Clinical Oncology.2. This article is hoste...
The United States (US) Food and Drug Administration (FDA) approves new drugs based on sponsor-submit...
Background: When the publication of important trial data is delayed, or data are never publish...